Controlled Clinical Trials
DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 20, Number 1, 1999

LLOYD D. FISHER AND LEMUEL A. MOYÉ
Carvedilol and the Food and Drug Administration Approval Process: An Introduction 1

LLOYD D. FISHER
Carvedilol and the Food and Drug Administration (FDA) Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing 16

LEMUEL A. MOYÉ
End-Point Interpretation in Clinical Trials: The Case for Discipline 40

LLOYD D. FISHER
Carvedilol and the Food and Drug Administration-Approval Process: A Brief Response to Professor Moyé's Article 50

BRUCE THOMPSON, NANCY L. GELLER, SALLY HUNSBERGER, MARGARET FREDERICK, ROBIN HILL, ROLF G. JACOB, EDWIN A. SMITH, PETER KAUFMANN, ROBERT R. FREEDMAN, FREDERICK M. WIGLEY, AND LEONARD BIELORY
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study 52

Book Reviews 64

Software Review 68

Design Papers

WAFAIE W. FAWZI, GERNARD I. MSAMANGA, DONNA SPIEGELMAN, ERNEST J. N. URASSA, AND DAVID J. HUNTER
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial 75

CHILDHOOD ASTHMA MANAGEMENT PROGRAM RESEARCH GROUP
The Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods 91

Volume 20, Number 2, 1999

JANET WITTES, EDWARD LAKATOS, DENNIS BLACK, BARBARA GERACI, BARRY DAVIS, LEMUEL MOYÉ, AND JEFFREY PROBSTFIELD
Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program 121

NORA COSGROVE, NEMAT O. BORHANI, GERI BAILEY, PATTY BORHANI, JULIE LEVIN, MARY HOFFMEIER, SUSAN KRIEGER, LAURA C. LOVATO, HELEN PETROVITCH, THOMAS VOGT, ALAN C. WILSON, VINCENT BREESON, JEFFREY L. PROBSTFIELD, FOR THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM (SHEP) COOPERATIVE RESEARCH GROUP
Mass Mailing and Staff Experience in a Total Recruitment Program for a Clinical Trial: The SHEP Experience 133

Controlled Clinical Trials
DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 20, Number 1, 1999

LLOYD D. FISHER AND LEMUEL A. MOYÉ
Carvedilol and the Food and Drug Administration Approval Process: An Introduction 1

LLOYD D. FISHER
Carvedilol and the Food and Drug Administration (FDA) Approval Process: The FDA Paradigm and Reflections on Hypothesis Testing 16

LEMUEL A. MOYÉ
End-Point Interpretation in Clinical Trials: The Case for Discipline 40

LLOYD D. FISHER
Carvedilol and the Food and Drug Administration-Approval Process: A Brief Response to Professor Moyé's Article 50

BRUCE THOMPSON, NANCY L. GELLER, SALLY HUNSBERGER, MARGARET FREDERICK, ROBIN HILL, ROLF G. JACOB, EDWIN A. SMITH, PETER KAUFMANN, ROBERT R. FREEDMAN, FREDERICK M. WIGLEY, AND LEONARD BIELORY
Behavioral and Pharmacologic Interventions: The Raynaud's Treatment Study 52

Book Reviews 64

Software Review 68

Design Papers

WAFAIE W. FAWZI, GERNARD I. MSAMANGA, DONNA SPIEGELMAN, ERNEST J. N. URASSA, AND DAVID J. HUNTER
Rationale and Design of the Tanzania Vitamin and HIV Infection Trial 75

CHILDHOOD ASTHMA MANAGEMENT PROGRAM RESEARCH GROUP
The Childhood Asthma Management Program (CAMP): Design, Rationale, and Methods 91

Volume 20, Number 2, 1999

JANET WITTES, EDWARD LAKATOS, DENNIS BLACK, BARBARA GERACI, BARRY DAVIS, LEMUEL MOYÉ, AND JEFFREY PROBSTFIELD
Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program 121

NORA COSGROVE, NEMAT O. BORHANI, GERI BAILEY, PATTY BORHANI, JULIE LEVIN, MARY HOFFMEIER, SUSAN KRIEGER, LAURA C. LOVATO, HELEN PETROVITCH, THOMAS VOGT, ALAN C. WILSON, VINCENT BREESON, JEFFREY L. PROBSTFIELD, FOR THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM (SHEP) COOPERATIVE RESEARCH GROUP
Mass Mailing and Staff Experience in a Total Recruitment Program for a Clinical Trial: The SHEP Experience 133

CLAIRE SNOWDON, DIANA ELBOURNE, AND JO GARCIA
Zelen Randomization: Attitudes of Parents Participating in a Neonatal Clinical Trial 149

CHRISTOPHER R. PALMER AND WILLIAM F. ROSENBERGER
Ethics and Practice: Alternative Designs for Phase III Randomized Clinical Trials 172

PHILIP W. LAVORI, JEREMY SUGARMAN, MARGUERITE T. HAYS, AND JOHN R. FEUSSNER
Improving Informed Consent in Clinical Trials: A Duty to Experiment 187

EUGENIO SANTORO, ENRICO NICOLIS, MARIA GRAZIA FRANZOSI, AND GIANNI TOGNONI
Internet for Clinical Trials: Past, Present, and Future 194

Software Review 202

List of Reviewers 205

Volume 20, Number 3, 1999

PETER ARMITAGE ON BEHALF OF THE CONCORDE AND ALPHA DATA AND SAFETY MONITORING COMMITTEE
Data and Safety Monitoring in the Concorde and Alpha Trials 207

PETER ARMITAGE ON BEHALF OF THE DELTA DATA AND SAFETY MONITORING COMMITTEE
Data and Safety Monitoring in the Delta Trial 229

DANIEL J. SARGENT, JEFF A. SLOAN, AND STEVEN S. CHA
Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations 242

JOHN P.A. IOANNIDIS, DENNIS O. DIXON, MARTIN MCINTOSH, JEFFREY M. ALBERT, SAMUEL A. BOZZETTE, AND STEVEN A. SCHNITTMAN
Relationship Between Event Rates and Treatment Effects in Clinical Site Differences Within Multicenter Trials: An Example from Primary *Pneumocystis carinii* Prophylaxis 253

PAULA DIEHR, DONALD L. PATRICK, GREGORY L. BURKE, AND JEFF WILLIAMSON
Survival Versus Years of Healthy Life: Which Is More Powerful as a Study Outcome? 267

PHYLLIS A. GIMOTTY, ROBERT C. BURACK, AND JULIE GEORGE
A Randomized Design for Repeated Binary Outcomes Used to Evaluate Continued Effectiveness of a Breast Cancer Control Intervention Strategy 280

Book Review 294

Design Paper

EDWARD O. MCFALLS, HERBERT B. WARD, WILLIAM C. KRUPSKI, STEVEN GOLDMAN, FRED LITTOOY, KIM EAGLE, JOHN A. NYMAN, THOMAS MORITZ, STACY MCNABB, AND WILLIAM G. HENDERSON FOR THE VETERANS AFFAIRS COOPERATIVE STUDY GROUP ON CORONARY ARTERY REVASCULARIZATION PROPHYLAXIS FOR ELECTIVE VASCULAR SURGERY
Prophylactic Coronary Artery Revascularization for Elective Vascular Surgery: Study Design 297

Volume 20, Number 4, 1999

DANIEL F. HEITJAN
Causal Inference in a Clinical Trial: A Comparative Example 309

VANCE W. BERGER AND DEREK V. EXNER
Detecting Selection Bias in Randomized Clinical Trials 319

WILLIAM F. ROSENBERGER
Randomized Play-the-Winner Clinical Trials: Review and Recommendations 328

P.Y. LIU, MICHAEL LEBLANC, AND MANISHA DESAI
False Positive Rates of Randomized Phase II Designs 343

MYRON N. CHANG, JONATHAN J. SHUSTER, AND JAMES L. KEPNER
Group Sequential Designs for Phase II Trials With Historical Controls 353

Book Review 365

Letter to the Editor 367

Design Papers

ROBERT G. HOLLOWAY, DAVID R. GIFFORD, MARTIN R. FRANKEL, AND BARBARA G. VICKREY
A Randomized Trial to Implement Practice Recommendations: Design and Methods of the Dementia Care Study 369

BEPPIE S.P. HELLEMONS, MACHTELD LANGENBERG, JAN LODDER, FRANK VERMEER, HUBERT J.A. SCHOUTEN, THEY G.J. LEMMENS, JAN W. VAN REE, AND J. ANDRÉ KNOTTNERUS
Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF Trial Study Design 386

Volume 20, Number 5, 1999

BORIS FREIDLIN, EDWARD L. KORN, AND STEPHEN L. GEORGE
Data Monitoring Committees and Interim Monitoring Guidelines 395

JOHN M. LACHIN
Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials 408

MINGGAO GU AND TZE·LEUNG LAI
Determination of Power and Sample Size in the Design of Clinical Trials with Failure-Time Endpoints and Interim Analyses 423

EMMANUEL LESAFFRE AND GORDON PLEDGER
A Note on the Number Needed to Treat 439

HEATHER D. CLARK, GEORGE A. WELLS, CHARLOTTE HUËT, FINLAY A. MCALISTER, L. RACHID SALMI, DEAN FERGUSSON, AND ANDREAS LAUPACIS
Assessing the Quality of Randomized Trials: Reliability of the Jadad Scale 448

DAVID SALSBURG
Why Analysis of Variance Is Inappropriate for Multiclinic Trials 453

Commentary

WEICHUNG JOE SHIH
Comment on "Why Analysis of Variance is Inappropriate for Multiclinic Trials" by David Salsburg 469

Book Reviews 472

Letter to the Editor 476

Design Papers

NICK FREEMANTLE, MARTIN ECCLES, JOHN WOOD, JAMES MASON, IRWIN NAZARETH, CATHERINE DUGGAN, PHILIP YOUNG, ANDREW HAINES, MIKE DRUMMOND, IAN RUSSELL, AND TOM WALLEY
A Randomized Trial of Evidence-Based Outreach (EBOR): Rationale and Design 479

BARRY I. FREEDMAN, JEAN-PAUL WUERTH, KENNETH CARTWRIGHT, RAYMOND P. BAIN, STEPHEN DIPPE, KENNETH HERSHON, ARSHAG D. MOORADIAN, AND BRUCE S. SPINOWITZ FOR THE ACTION II STUDY INVESTIGATORS
Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II) 493

Volume 20, Number 6, 1999

JOSEF HÖGEL AND WILHELM GAUS
The Procedure of New Drug Application and the Philosophy of Critical Rationalism or The Limits of Quality Assurance with Good Clinical Practice 511

GERHARD SVOLBA AND PETER BAUER
Statistical Quality Control in Clinical Trials 519

KRISTA FISCHER-LAPP AND ELS GOETGHEBEUR
Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials 531

RORY WOLFE AND JOHN B. CARLIN
Sample-Size Calculation for a Log-Transformed Outcome Measure 547

JOHN J. HANFELT, REBECCA S. SLACK AND EDMUND A. GEHAN
A Modification of Simon's Optimal Design for Phase II Trials When the Criterion Is Median Sample Size 555

Commentary

JANET DARBYSHIRE
Confirmatory Trials—A New Approach? 567

Letters to the Editor 569

Design Papers

THE AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP
The Age-Related Eye Disease Study (AREDS): Design Implications AREDS Report No. 1 573

DOUGLASS A. MORRISON, GULSHAN SETHI, JEROME SACKS, FREDERICK GROVER, STEVEN SEDLIS, RICK ESPOSITO, K.B. RAMANATHAN, DARRYL WEIMAN, MITCHELL KRUCOFF, FRANCIS DUHAYLONGSOD, THOMAS RAYA, STUART PETT, SARAH VERNON, VALDIMIR BIRJINIUK, DAVID BOOTH, CLIVE ROBINSON, J. DAVID TALLEY, TAMIM ANTCKLI, EDWARD MURPHY, HARKNESS FLOTEN, VLADIMIR CURCOVIC, JOHN C. LUCKE, DAN LEWIS, CHARLES BARBIERE, AND WILLIAM HENDERSON FOR THE AWESOME (VETERANS AFFAIRS COOPERATIVE STUDY #385, ANGINA WITH EXTREMELY SERIOUS OPERATIVE MORTALITY EVALUATION) INVESTIGATORS FROM THE COOPERATIVE STUDIES PROGRAM OF THE DEPARTMENT OF VETERANS AFFAIRS
A Multicenter, Randomized Trial of Percutaneous Coronary Intervention Versus Bypass Surgery in High-Risk Unstable Angina Patients 601

Author Index 620

Subject Index 622

Volume Contents 632